CME Group Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by CME Group Inc. on September 5, 2012, reporting events occurring on September 5 and September 10, 2012. The filing details the entry into a material definitive agreement regarding a new public debt offering.
Key Financial Metrics and Debt Structure
- New Debt Issuance: Completed a public offering of $750,000,000 aggregate principal amount of 3.00% Notes due 2022.
- Interest Rate: Coupon rate is 3.00%. Through a forward-starting interest rate swap entered in August 2012, the effective annual interest rate is estimated at 3.375%.
- Pricing: Notes were sold to underwriters at 99.041% of principal and offered to the public at 99.691% of principal.
- Payment Schedule: Interest is payable semi-annually on March 15 and September 15, commencing March 15, 2013.
- Use of Proceeds: Net proceeds, combined with cash on hand, are intended to retire outstanding 5.40% notes due in August 2013 at maturity. Remaining proceeds may be used for general corporate purposes.
Material Changes and Obligations
The primary material change is the creation of a direct financial obligation via the issuance of the 2022 Notes. The company entered into an Underwriting Agreement with Barclays Capital Inc., Merrill Lynch, Pierce, Fenner & Smith Incorporated, and UBS Securities LLC. The Notes are issued under a Base Indenture dated August 12, 2008, supplemented by a Fifth Supplemental Indenture dated September 10, 2012.
The Indenture includes covenants limiting the company's ability to incur certain liens, engage in specific sale and leaseback transactions, and consolidate or transfer substantially all assets. A change of control provision requires the company to offer to repurchase the Notes at 101% of principal plus accrued interest if a change of control occurs and the Notes are downgraded below investment grade by both Moody's and S&P within a specified period.
Outlook, Risks, and Contingencies
The filing does not provide specific revenue guidance or management commentary on future operating performance. The primary contingency noted is the potential use of proceeds for general corporate purposes if the refinancing of the 2013 notes does not consume the full amount. The filing also discloses that underwriters and their affiliates have existing commercial banking, investment banking, and advisory relationships with the company and may act as agents or lenders under the company's credit facilities.
Investor Verification Checklist
- Verify the exact net proceeds received after underwriting discounts and expenses.
- Confirm the specific terms of the forward-starting interest rate swap agreement to validate the 3.375% effective rate.
- Review the full text of the Fifth Supplemental Indenture (Exhibit 4.2) for detailed covenants and repurchase triggers.
- Check the status of the outstanding 5.40% notes due August 2013 to confirm the refinancing timeline.
- Assess the impact of the new debt issuance on the company's overall leverage ratios and fixed charge coverage.